期刊
JOURNAL OF NEUROVIROLOGY
卷 25, 期 2, 页码 284-287出版社
SPRINGER
DOI: 10.1007/s13365-019-00738-x
关键词
Progressive multifocal leukoencephalopathy; PML; Nivolumab; PD-1 inhibitor; JC virus
资金
- NIAID NIH HHS [UM1 AI069495] Funding Source: Medline
Therapy for progressive multifocal leukoencephalopathy (PML) remains challenging since there are no antiviral therapies available for JC virus. Immune reconstitution has improved the prognosis in many settings where PML occurs, but it often is not possible in PML patients with hematologic malignancies. We describe the first biopsy proven PML case where the PD-1 inhibitor nivolumab appears to have stimulated immune activation resulting in effective control of PML in a patient with hematologic malignancy. This report supports further investigation of the utility of checkpoint inhibitors for treating PML where other immune reconstitution options are not available.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据